Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radioactive drug aims to slow advanced prostate cancer in major trial

NCT ID NCT07611110

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 4 times

Summary

This study tests a new drug called AZD2265, which delivers radiation directly to prostate cancer cells. It is for people with a type of advanced prostate cancer that no longer responds to hormone therapy. The trial compares the new drug to standard treatments to see if it can slow cancer growth and help people live longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 670 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age. * Diagnosis of adenocarcinoma of prostate. * Must have had prior orchiectomy and/or ongoing ADT and a castrate level of plasma/serum testosterone. * Progressive mCRPC following the most recent treatment at the time of study entry, with at least 1 metastatic lesion (measurable and/or non-measurable) that is suitable for repeated assessment by CT and/or MRI and/or bone scan. * Previously treated with at least 2 cycles of PSMA-directed β-emitting radioconjugate. * Previously treated with at least 1 taxane-based chemotherapy regimen for either metastatic hormone-sensitive prostate cancer or CRPC. * Previously treated with at least 1 ARPI (eg, enzalutamide, abiraterone, etc.). * Positive PSMA PET/CT scans, obtained with PSMA ligands (⁶⁸Ga-PSMA-11 or ¹⁸F-DCFPyL). * ECOG performance status of 0 to 2. * Adequate organ and bone marrow function as described in study protocol. * Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention. * Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners. Exclusion Criteria: * Prior treatment with an α-emitting molecular targeted therapeutic radioconjugate (prior treatment with radium-223 is permitted). * Progression on PSMA-directed β-emitting radioconjugate prior to the administration of Cycle 3. * Receipt of \> 6 cycles of PSMA-directed β-emitting therapeutic RC. * History of another primary malignancy, with exceptions. * Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, with exceptions. * Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention. * Clinically significant ECG abnormalities, with exceptions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    129 sites in 20 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Dothan, Alabama, 36303, United States

  • Research Site

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85004, United States

  • Research Site

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

  • Research Site

    NOT_YET_RECRUITING

    Irvine, California, 92618, United States

  • Research Site

    RECRUITING

    Newport Beach, California, 92660, United States

  • Research Site

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

  • Research Site

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

  • Research Site

    RECRUITING

    Miami, Florida, 33165, United States

  • Research Site

    NOT_YET_RECRUITING

    O'Fallon, Illinois, 62269, United States

  • Research Site

    RECRUITING

    Metairie, Louisiana, 70006, United States

  • Research Site

    WITHDRAWN

    Detroit, Michigan, 48201, United States

  • Research Site

    NOT_YET_RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Research Site

    NOT_YET_RECRUITING

    St Louis, Missouri, 63104, United States

  • Research Site

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Research Site

    NOT_YET_RECRUITING

    Albuquerque, New Mexico, 87109, United States

  • Research Site

    NOT_YET_RECRUITING

    New Hyde Park, New York, 11042, United States

  • Research Site

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

  • Research Site

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Research Site

    NOT_YET_RECRUITING

    Dayton, Ohio, 45415, United States

  • Research Site

    NOT_YET_RECRUITING

    Portland, Oregon, 97239, United States

  • Research Site

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    NOT_YET_RECRUITING

    Myrtle Beach, South Carolina, 29572, United States

  • Research Site

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77042, United States

  • Research Site

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84106, United States

  • Research Site

    NOT_YET_RECRUITING

    Tacoma, Washington, 98405, United States

  • Research Site

    NOT_YET_RECRUITING

    Darlinghurst, 2010, Australia

  • Research Site

    NOT_YET_RECRUITING

    Kurralta Park, 5037, Australia

  • Research Site

    NOT_YET_RECRUITING

    Melbourne, 3000, Australia

  • Research Site

    NOT_YET_RECRUITING

    Murdoch, WA6150, Australia

  • Research Site

    NOT_YET_RECRUITING

    Linz, 4020, Austria

  • Research Site

    NOT_YET_RECRUITING

    Salzburg, 5020, Austria

  • Research Site

    NOT_YET_RECRUITING

    São Paulo, 01308-050, Brazil

  • Research Site

    NOT_YET_RECRUITING

    São Paulo, 05652-900, Brazil

  • Research Site

    NOT_YET_RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

  • Research Site

    NOT_YET_RECRUITING

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Research Site

    NOT_YET_RECRUITING

    Hamilton, Ontario, L8V 1C3, Canada

  • Research Site

    NOT_YET_RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Research Site

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    NOT_YET_RECRUITING

    Montreal, Quebec, H3A 1A1, Canada

  • Research Site

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100034, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100142, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, 610041, China

  • Research Site

    NOT_YET_RECRUITING

    Chongqing, 400030, China

  • Research Site

    NOT_YET_RECRUITING

    Fuzhou, 350005, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510060, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510120, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510630, China

  • Research Site

    NOT_YET_RECRUITING

    Hangzhou, 310003, China

  • Research Site

    NOT_YET_RECRUITING

    Hangzhou, 310014, China

  • Research Site

    NOT_YET_RECRUITING

    Hangzhou, 310022, China

  • Research Site

    NOT_YET_RECRUITING

    Jinan, 250117, China

  • Research Site

    NOT_YET_RECRUITING

    Nanjing, 210006, China

  • Research Site

    SUSPENDED

    Nanjing, 210029, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 200025, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 200032, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, 110001, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430022, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430030, China

  • Research Site

    NOT_YET_RECRUITING

    Xi'an, 710061, China

  • Research Site

    NOT_YET_RECRUITING

    Kuopio, 70210, Finland

  • Research Site

    NOT_YET_RECRUITING

    Villejuif, 94800, France

  • Research Site

    NOT_YET_RECRUITING

    Augsburg, 86156, Germany

  • Research Site

    NOT_YET_RECRUITING

    Berlin, 13353, Germany

  • Research Site

    NOT_YET_RECRUITING

    Bonn, 53127, Germany

  • Research Site

    NOT_YET_RECRUITING

    Cologne, 50937, Germany

  • Research Site

    NOT_YET_RECRUITING

    Dresden, 01307, Germany

  • Research Site

    NOT_YET_RECRUITING

    Essen, 45122, Germany

  • Research Site

    NOT_YET_RECRUITING

    Jena, 07747, Germany

  • Research Site

    WITHDRAWN

    Karlsruhe, 76133, Germany

  • Research Site

    NOT_YET_RECRUITING

    München, 81675, Germany

  • Research Site

    NOT_YET_RECRUITING

    Münster, 48149, Germany

  • Research Site

    WITHDRAWN

    Nuremberg, 90419, Germany

  • Research Site

    NOT_YET_RECRUITING

    Rostock, 18057, Germany

  • Research Site

    NOT_YET_RECRUITING

    Stuttgart, 70174, Germany

  • Research Site

    NOT_YET_RECRUITING

    Tübingen, 72076, Germany

  • Research Site

    NOT_YET_RECRUITING

    Würzburg, 97080, Germany

  • Research Site

    NOT_YET_RECRUITING

    Bangalore, 560017, India

  • Research Site

    NOT_YET_RECRUITING

    Gurgaon, 122001, India

  • Research Site

    NOT_YET_RECRUITING

    Gurgaon, 122002, India

  • Research Site

    NOT_YET_RECRUITING

    Navi Mumbai, 410210, India

  • Research Site

    NOT_YET_RECRUITING

    Haifa, 3109601, Israel

  • Research Site

    NOT_YET_RECRUITING

    Jerusalem, 00000, Israel

  • Research Site

    NOT_YET_RECRUITING

    Petah Tikva, 4941492, Israel

  • Research Site

    NOT_YET_RECRUITING

    Ramat Gan, 52621, Israel

  • Research Site

    NOT_YET_RECRUITING

    Tel Aviv, 64239, Israel

  • Research Site

    NOT_YET_RECRUITING

    Chiba, 260-8717, Japan

  • Research Site

    NOT_YET_RECRUITING

    Chūōku, 104-0045, Japan

  • Research Site

    RECRUITING

    Fukuoka, 812-8582, Japan

  • Research Site

    NOT_YET_RECRUITING

    Hamamatsu, 431-3192, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kamakura-shi, 247-8533, Japan

  • Research Site

    RECRUITING

    Kanazawa, 920-8641, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kashiwa, 227-8577, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kobe, 650-0047, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kyoto, 606-8507, Japan

  • Research Site

    RECRUITING

    Sapporo, 060-8638, Japan

  • Research Site

    NOT_YET_RECRUITING

    Suita-shi, 565-0871, Japan

  • Research Site

    NOT_YET_RECRUITING

    Yokohama, 236-0004, Japan

  • Research Site

    NOT_YET_RECRUITING

    Gdansk, 80-214, Poland

  • Research Site

    NOT_YET_RECRUITING

    Krakow, 31-501, Poland

  • Research Site

    NOT_YET_RECRUITING

    Warsaw, 02-781, Poland

  • Research Site

    NOT_YET_RECRUITING

    Goyang-si, 10408, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 06591, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 3722, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 5505, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 6351, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 08025, Spain

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 8035, Spain

  • Research Site

    NOT_YET_RECRUITING

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28041, Spain

  • Research Site

    NOT_YET_RECRUITING

    Majadahonda, 28222, Spain

  • Research Site

    NOT_YET_RECRUITING

    Málaga, 29009, Spain

  • Research Site

    NOT_YET_RECRUITING

    Santiago de Compostela, 15706, Spain

  • Research Site

    NOT_YET_RECRUITING

    Stockholm, 17176, Sweden

  • Research Site

    NOT_YET_RECRUITING

    Umeå, 901 85, Sweden

  • Research Site

    NOT_YET_RECRUITING

    Kaohsiung City, 833401, Taiwan

  • Research Site

    NOT_YET_RECRUITING

    Taipei, 10002, Taiwan

  • Research Site

    NOT_YET_RECRUITING

    Taipei, 11217, Taiwan

  • Research Site

    NOT_YET_RECRUITING

    Taipei, 11259, Taiwan

  • Research Site

    NOT_YET_RECRUITING

    Taoyuan, 333, Taiwan

  • Research Site

    NOT_YET_RECRUITING

    Bangkok, 10210, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Bangkok, 10700, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Ankara, 06530, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Ankara, 06620, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Istanbul, 34098, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Istanbul, 34752, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    London, EC1A 7BE, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Middlesbrough, TS4 3BW, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Truro, TR1 3LJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.